European addiction research · 2025
UK Medical Cannabis Registry: A Clinical Analysis of Patients with Substance Use Disorder.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ghosh Aishwarya, Erridge Simon, Coomber Ross, Bhoskar Urmila, Holden Wendy, Kamal Fariha, Mwimba Gracia, Sachdeva-Mohan Simmi, Shaya Gabriel, Usmani Azfer, Rucker James, Sodergren Mikael
Аннотация
INTRODUCTION: With a global rise in opioid-related mortality, there comes a need to address this with novel therapies. Cannabinoid receptors are highly expressed and co-localised with opiate receptors of the mesolimbic system. Cannabis-based medicinal products (CBMPs) have been suggested as a measure to reduce harm as maintenance therapy for substance use disorder (SUD). This aim of this study was to assess changes in patient-reported outcomes measures (PROMs) and opioid medications in individuals treated with CBMPs for SUD.
METHODS: Data from patients with SUD from the UK Medical Cannabis Registry were analysed. Outcomes included changes at 1, 3, and 6 months from baseline of the EQ-5D-DL, single-item sleep quality scale (SQS), and Generalised Anxiety Disorder-7 (GAD-7) questionnaire. Change in opioid medications was assessed as change in oral morphine equivalent (OME).
RESULTS: 34 patients were included. Twenty-seven (79.41%) participants were male. Twenty-nine (85.29%) participants were illicit cannabis consumers at baseline. The most common SUD was opioid use disorder (n = 18; 52.94%). Four (11.76%), 14 (41.18%), and 16 (47.05%) patients were prescribed oils, dried flower, or a combination of dried flower and oils, respectively. Improvements in GAD-7, SQS, and EQ-5D-5L at 1, 3, and 6 months from baseline were observed (p < 0.050). Median OME consumption at baseline was 274.95 (79.50-441.80) mg/day. This was reduced at 6 months (204.45 [61.88-354.85] mg/day; p = 0.043), there was no significant difference at 1 or 3 months (p > 0.050). Three (8.81%) participants reported 17 (50.00%) adverse events.
CONCLUSIONS: There was an associated improvement in health-related quality of life PROMs and reduction in prescribed opioids in individuals with SUD treated with CBMPs. CBMPs were well tolerated by most individuals in this 6-month analysis. Further evaluation through randomised controlled trials is needed to determine causality.
METHODS: Data from patients with SUD from the UK Medical Cannabis Registry were analysed. Outcomes included changes at 1, 3, and 6 months from baseline of the EQ-5D-DL, single-item sleep quality scale (SQS), and Generalised Anxiety Disorder-7 (GAD-7) questionnaire. Change in opioid medications was assessed as change in oral morphine equivalent (OME).
RESULTS: 34 patients were included. Twenty-seven (79.41%) participants were male. Twenty-nine (85.29%) participants were illicit cannabis consumers at baseline. The most common SUD was opioid use disorder (n = 18; 52.94%). Four (11.76%), 14 (41.18%), and 16 (47.05%) patients were prescribed oils, dried flower, or a combination of dried flower and oils, respectively. Improvements in GAD-7, SQS, and EQ-5D-5L at 1, 3, and 6 months from baseline were observed (p < 0.050). Median OME consumption at baseline was 274.95 (79.50-441.80) mg/day. This was reduced at 6 months (204.45 [61.88-354.85] mg/day; p = 0.043), there was no significant difference at 1 or 3 months (p > 0.050). Three (8.81%) participants reported 17 (50.00%) adverse events.
CONCLUSIONS: There was an associated improvement in health-related quality of life PROMs and reduction in prescribed opioids in individuals with SUD treated with CBMPs. CBMPs were well tolerated by most individuals in this 6-month analysis. Further evaluation through randomised controlled trials is needed to determine causality.